Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.4641
USD
|
+1.11%
|
|
-3.89%
|
-49.20%
|
Fiscal Period: Maart |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
646.5
|
1,713
|
1,043
|
224.1
|
-
|
-
|
Enterprise Value (EV)
1 |
646.5
|
1,159
|
655.7
|
224.1
|
224.1
|
224.1
|
P/E ratio
|
-2.4
x
|
-6.38
x
|
-3.3
x
|
-0.42
x
|
-0.79
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
6.3
x
|
3.48
x
|
1.03
x
|
0.85
x
|
0.74
x
|
EV / Revenue
|
-
|
6.3
x
|
3.48
x
|
1.03
x
|
0.85
x
|
0.74
x
|
EV / EBITDA
|
-
|
-11.4
x
|
-6.46
x
|
0.69
x
|
-1.22
x
|
-1.45
x
|
EV / FCF
|
-
|
-9,471,803
x
|
-6,152,856
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
1.88
x
|
1.47
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
63,569
|
447,129
|
457,249
|
482,917
|
-
|
-
|
Reference price
2 |
10.17
|
3.830
|
2.280
|
0.4641
|
0.4641
|
0.4641
|
Announcement Date
|
6/21/21
|
5/26/22
|
5/25/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
271.9
|
299.5
|
217.1
|
265
|
303.6
|
EBITDA
1 |
-
|
-150.7
|
-161.3
|
325.7
|
-183.7
|
-154.4
|
EBIT
1 |
-
|
-267.8
|
-314
|
-548.3
|
-305.8
|
-278.2
|
Operating Margin
|
-
|
-98.51%
|
-104.86%
|
-252.62%
|
-115.37%
|
-91.63%
|
Earnings before Tax (EBT)
|
-
|
-221
|
-314.4
|
-
|
-
|
-
|
Net income
|
-183.6
|
-217.5
|
-311.7
|
-
|
-
|
-
|
Net margin
|
-
|
-79.99%
|
-104.06%
|
-
|
-
|
-
|
EPS
2 |
-4.230
|
-0.6000
|
-0.6900
|
-1.100
|
-0.5900
|
-
|
Free Cash Flow
|
-
|
-180.8
|
-169.4
|
-
|
-
|
-
|
FCF margin
|
-
|
-66.5%
|
-56.58%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/21/21
|
5/26/22
|
5/25/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
55.2
|
56.89
|
100.6
|
64.51
|
75.66
|
66.94
|
92.38
|
60.86
|
50
|
44.75
|
61.45
|
63.85
|
64.91
|
61.57
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-29.66
|
-43.27
|
-
|
-
|
-
|
-
|
-65.04
|
-64.36
|
-25.38
|
-28.25
|
EBIT
1 |
-46.45
|
-96.7
|
-59.31
|
-89.6
|
-68.04
|
-97.1
|
-69.27
|
-
|
-
|
-
|
-78.72
|
-103.4
|
-65
|
-68.53
|
Operating Margin
|
-84.14%
|
-169.98%
|
-58.98%
|
-138.88%
|
-89.93%
|
-145.06%
|
-74.99%
|
-
|
-
|
-
|
-128.11%
|
-161.97%
|
-100.14%
|
-111.32%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-67.34
|
-92.57
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-66.06
|
-91.96
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-87.32%
|
-137.38%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-0.0400
|
-0.2100
|
-0.1600
|
-0.2000
|
-0.1500
|
-0.2000
|
-0.1400
|
-0.2300
|
-0.1600
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
2/10/22
|
5/26/22
|
8/8/22
|
11/7/22
|
2/8/23
|
5/25/23
|
8/8/23
|
11/8/23
|
2/7/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
553
|
387
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-181
|
-169
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-136%
|
-38.2%
|
0.01%
|
-38.7%
|
-41.3%
|
ROA (Net income/ Total Assets)
|
-
|
-28.8%
|
-
|
-
|
-
|
-
|
Assets
|
-
|
755.3
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
2.040
|
1.550
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-0.3700
|
-
|
-
|
-
|
Capex
|
-
|
14
|
4.05
|
-
|
-
|
-
|
Capex / Sales
|
-
|
5.14%
|
1.35%
|
-
|
-
|
-
|
Announcement Date
|
6/21/21
|
5/26/22
|
5/25/23
|
-
|
-
|
-
|
Last Close Price
0.4641
USD Average target price
1.425
USD Spread / Average Target +207.05% Consensus |
1st Jan change
|
Capi.
|
---|
| -49.20% | 224M | | -17.89% | 8.25B | | +39.20% | 3.58B | | -39.11% | 2.46B | | -8.06% | 2.46B | | -7.35% | 2.38B | | -12.61% | 1.81B | | -19.01% | 1.55B | | -40.66% | 1.21B | | +7.56% | 1.11B |
Medical & Diagnostic Laboratories
|